Skip to main content
Researchers at Seqirus Holly Springs)


Leaders in influenza

CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.

Globally we utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection.

As part of the CSL Group, we have been producing egg-based influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.

Little boy with bandaid

About Influenza

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people.

Learn more
  • 3 to 5 million

    Cases of severe illness resulting from annual flu epidemics.*

  • up to 650,000

    potential respiratory deaths linked to seasonal flu each year.*

  • US$27 billion

    Annual medical care and lost labour costs in the US alone.^

Areas of expertise



We are one of the world’s largest influenza vaccine companies with a singular global focus on influenza.


Pandemic Response Solutions

Experts agree that there will be another influenza pandemic this century1. CSL Seqirus offers a portfolio of pandemic vaccines and services for rapid response.

Consumer Pain Campaign AU 1


CSL Seqirus is the largest fully integrated commercialisation partner for vaccines and pharmaceuticals in Australia and New Zealand.

AVAT / Q Vax - red bellied black snake

Antivenoms & Q fever Vaccine

CSL Seqirus is the supplier of a unique range of antivenoms and Q fever vaccine for the Australian government.

*World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: (Accessed March 2019)
^de Boer, P. et al, A systematic review of health economic consequences of quadrivalent influenza vaccination, Expert review of Pharmacoeconomics & Outcomes Research, Volume 17, 2017 - Issue 3, p249-265.
World Health Organisation. Newsroom Feature. 8 Things to know about pandemic influenza. Available online: (Accessed June 2019)